SepsisNCT07924501
AI-ECHO Hemodynamic Phenotyping in Septic Shock
An observational study of Sepsis and Septic Shock, run by Second Affiliated Hospital of Guangzhou Medical University at 1 site in China.
Trial summary
This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sepsis, Septic Shock, Septic Cardiomyopathy
- What is being tested?
- Point-of-care echocardiography
- How many people
- 240 participants
- Where
- 1 siteChina
- Study dates
- 30 Nov 2026to 30 Nov 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a prospective observational cohort study enrolling adult patients with septic shock admitted to the ICU. The study aims to construct a multi-dimensional clinical-echocardiographic database, develop an AI-based automatic echocardiographic analysis system, identify hemodynamic subtypes using unsupervised machine learning, and reveal the dynamic evolution patterns of hemodynamics in septic shock.
Who may be able to join
- Age ≥18 years.
- Confirmed diagnosis of septic shock according to the Sepsis-3 criteria.
- Expected ICU stay of at least 72 hours.
- Written informed consent obtained from the patient or legally authorized representative.
Who cannot join
- Patients meeting any of the following criteria will be excluded:
- Severe chronic heart disease, such as severe valvular heart disease or chronic heart failure with left ventricular ejection fraction (LVEF) <30%.
- Acute coronary syndrome.
- Status post cardiac surgery.
- Pregnancy.
- Inability to obtain high-quality echocardiographic images at screening.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 511436
Weiyan Chen, MD, PhD, +86 13751845652, sam11124@163.com
Lili, Tao, +86 020-34153246, taollicu@163.com
About this study
Official title: AI-ECHO-Based Intelligent Hemodynamic Subtyping and Dynamic Evolution in Septic Shock: A Prospective Observational Cohort Study
This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. The study will enroll 240 adult patients with septic shock admitted to the ICU. Standardized cardiac ultrasound examinations will be performed at multiple time points, and multi-dimensional clinical-echocardiographic data will be collected. An AI-based automatic echocardiographic analysis system will be developed, and unsupervised machine learning will be applied to identify distinct hemodynamic subtypes and their dynamic evolution trajectories. This study aims to provide innovative solutions for individualized and precise hemodynamic management of septic shock.
Read the detailed description
Background
Septic shock is the most severe stage of sepsis and is associated with mortality as high as 40%-50%. Its pathophysiological core involves profound hemodynamic disturbances resulting from complex interactions among abnormal vascular tone, relative or absolute intravascular volume deficiency, myocardial depression, and microcirculatory dysfunction.
Accumulating evidence has demonstrated substantial heterogeneity in hemodynamic profiles among patients with septic shock, including hyperdynamic states, left ventricular systolic or diastolic dysfunction, right ventricular dysfunction, and various combined phenotypes. The traditional binary classification of "warm shock" versus "cold shock" is too simplistic to capture this complexity. Such heterogeneity may partly explain why uniform treatment strategies, such as early goal-directed therapy, have yielded inconsistent results and may cause iatrogenic harm in certain subgroups.
Echocardiography has become an important tool for hemodynamic assessment in the intensive care unit (ICU). It enables noninvasive, real-time evaluation of cardiac structure and function, including left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), right ventricular function, diastolic function, cardiac output, and volume status. However, its clinical utility is limited by:
- High operator dependency and interobserver variability;
- Time-consuming post-processing and interpretation;
- Difficulty in performing frequent dynamic assessments in busy ICU settings; and
- Limited integrated analysis of multiple parameters over time.
Recent advances in artificial intelligence (AI), particularly deep learning, have shown considerable promise in medical image analysis. In echocardiography, AI has demonstrated promising performance in view classification, cardiac structure segmentation, and automated measurement of functional parameters. Meanwhile, unsupervised machine learning methods provide potential approaches for identifying disease subtypes from high-dimensional clinical data.
Building on the established "Guangzhou Sepsis Cohort" and prior research experience in AI-assisted critical care medicine, this study will integrate AI and echocardiography to systematically characterize hemodynamic phenotypes and their dynamic evolution in patients with septic shock.
Study Design
This is a prospective, single-center, observational cohort study. A total of 360 adults with septic shock admitted to the ICU of The Second Affiliated Hospital of Guangzhou Medical University are anticipated to be consecutively enrolled.
Echocardiographic examinations will be performed on Day 1, Day 3, and Day 7 after enrollment. Clinical data, laboratory measurements, treatment information, and clinical outcomes will be collected according to the study protocol.
At each echocardiographic time point, standardized point-of-care echocardiography will be performed using the same model of ultrasound system and a phased-array transducer. Cine loops of the apical four-chamber, two-chamber, and three-chamber views will be acquired for at least three cardiac cycles. Additional Doppler, M-mode, right ventricular-focused, left ventricular outflow tract, and inferior vena cava recordings will be acquired as required for the prespecified echocardiographic measurements and as detailed in the imaging manual. All images will be stored in de-identified DICOM format using a unique study identification code.
AI-derived measurements will be used for research purposes only and will not guide clinical management. Clinical treatment will be determined by the treating clinical team and will not be assigned by the study.
Clinical data collected at or near the echocardiographic examinations will include vital signs, laboratory measurements, fluid balance, vasopressor dosage, and other treatment information. Blood samples will be collected on Day 1, Day 3, and Day 7 for targeted proteomic and metabolomic analyses, as specified in the study protocol.
Study Objectives
Primary Objective:
To identify and characterize distinct hemodynamic subtypes of septic shock using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters.
Secondary Objectives:
- Longitudinal changes and dynamic evolution of hemodynamic status within 7 days after enrollment;
- Associations of hemodynamic phenotypes with clinical severity and clinical outcomes;
- Agreement between AI-derived and blinded expert echocardiographic measurements;
- Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes; and
- Exploratory development and internal validation of an early-warning model for 28-day all-cause mortality.
Study Population
Adults (≥18 years) with septic shock, diagnosed according to the Sepsis-3 criteria, who meet the eligibility criteria listed in the Eligibility section will be consecutively enrolled from the ICU of The Second Affiliated Hospital of Guangzhou Medical University. Eligible participants must have an expected ICU stay of at least 72 hours, and written informed consent must be obtained from the patient or a legally authorized representative.
Outcome Measures
Primary Outcome:
Hemodynamic subtypes identified using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters collected within 7 days after enrollment.
Secondary Outcomes:
- Agreement between AI-derived echocardiographic measurements and blinded expert reference measurements, evaluated using intraclass correlation coefficients and Bland-Altman analyses;
- Associations between hemodynamic subtypes and 28-day mortality;
- Associations between hemodynamic subtypes and organ failure severity, as assessed by the Sequential Organ Failure Assessment (SOFA) score;
- Duration of vasopressor use; and
- ICU and hospital lengths of stay.
Statistical Analysis
Sample Size Considerations: The planned enrollment of 240 participants is based on the anticipated number of eligible septic shock admissions during the recruitment period, expected consent and follow-up completion, and study feasibility. The target sample size is intended to provide an adequate dataset for exploratory hemodynamic phenotyping and longitudinal echocardiographic analyses. As the primary objective is exploratory hemodynamic phenotyping using unsupervised analysis, no formal hypothesis-based power calculation was performed. Analyses of clinical outcomes, multi-omics profiles, and early-warning models will be considered exploratory, and model complexity will be limited according to the effective sample size and number of observed events.
Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, as appropriate. Categorical variables will be summarized as frequencies and percentages.
An unsupervised Gaussian mixture model will be applied to identify hemodynamic subtypes based on prespecified echocardiographic parameters. Clinical characteristics, treatment information, and outcomes will be compared among the identified subtypes.
Agreement between AI-derived measurements and blinded expert reference measurements will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. Targeted proteomic and metabolomic analyses will evaluate associations between protein or metabolite abundances and hemodynamic phenotype membership using methods appropriate for high-dimensional data. Where applicable, the false discovery rate will be used to account for multiple comparisons. These analyses will be considered exploratory.
An exploratory early-warning model for 28-day all-cause mortality will be developed using prespecified candidate predictors. Model discrimination will be assessed using the area under the receiver operating characteristic curve, and calibration will be evaluated using calibration plots and calibration statistics. Internal validation will be performed using bootstrap resampling or cross-validation. The number of candidate predictors and model complexity will be limited according to the number of observed events to reduce the risk of overfitting.
Multivariable logistic regression or Cox proportional hazards models will be constructed, as appropriate, to explore factors associated with adverse clinical outcomes. Repeated measurements and missing data will be addressed according to the prespecified statistical analysis plan.
Statistical analyses will be performed using SPSS, R, and Python. A two-sided P value <0.05 will be considered statistically significant, with exploratory analyses interpreted accordingly.
- Conditions
- Sepsis, Septic Shock, Septic Cardiomyopathy
- Being tested
- Point-of-care echocardiography
- Keywords
- Point-of-Care Echocardiography, Septic Shock, Hemodynamics, Intensive Care Unit, Left Ventricular Ejection Fraction, Global Longitudinal Strain
- Medical subject headings
- Sepsis, Shock, Septic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Point-of-care echocardiographyOther
Standardized point-of-care echocardiography will be performed on Day 1, Day 3, and Day 7 after enrollment. Images will be acquired according to the imaging manual and stored in de-identified DICOM format using a unique study identification code. Echocardiographic parameters will be used for hemodynamic phenotyping and assessment of changes over time.
| Study group | Role | What they receive |
|---|---|---|
| Septic Shock Patients | Adults with septic shock admitted to the intensive care unit who meet the eligibility criteria listed in the Eligibility section. Participants will undergo standardized point-of-care echocardiography on Day 1, Day 3, and Day 7 after enrollment, together with clinical data and blood sample collection as specified in the study protocol. Clinical management will be determined by the treating clinical team and will not be assigned by the study. AI-derived echocardiographic measurements will be used for research purposes only and will not guide clinical management. Receives: Other: Point-of-care echocardiography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock
Identification and characterization of distinct hemodynamic phenotypes in adults with septic shock using unsupervised analysis of prespecified multidimensional echocardiographic parameters. The parameters may include measures of left ventricular systolic and diastolic function, right ventricular function, cardiac output or flow, and inferior vena cava dynamics, depending on data availability and image quality. The number and characteristics of the identified phenotypes will be determined using prespecified model selection and evaluation procedures.
Measured: Within 7 days after enrollment
Secondary outcomes (5)
Longitudinal Changes and Dynamic Evolution of Hemodynamic Status
Serial changes in echocardiographic parameters and transitions among hemodynamic phenotypes will be evaluated during follow-up.
Measured: Day 1, Day 3, and Day 7 after enrollment.
Associations Between Hemodynamic Phenotypes and Clinical Severity and Outcomes
Associations of hemodynamic phenotypes with SOFA score, blood lactate, 28-day all-cause mortality, vasopressor duration, and ICU and hospital length of stay will be evaluated.
Measured: Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
Agreement Between AI-Derived and Blinded Expert Echocardiographic Measurements
Agreement for prespecified echocardiographic parameters will be evaluated using intraclass correlation coefficients and Bland-Altman analyses.
Measured: Day 1, Day 3, and Day 7 after enrollment.
Associations Between Molecular Profiles and Hemodynamic Phenotypes
Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes will be evaluated.
Measured: Day 1, Day 3, and Day 7 after enrollment.
Exploratory Early-Warning Model for 28-Day All-Cause Mortality
An exploratory model will be developed and internally validated using clinical and echocardiographic data.
Measured: Predictors within 7 days; mortality through 28 days after enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2026
- Study start30 Nov 2026 (estimated)
- Primary completion9 Nov 2028 (estimated)
- Study completion30 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SepsisStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital of Guangzhou Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Hong Kong University of Science and Technology
- Responsible party
- Sponsor
- Investigators
- Weiyan Chen, MD, PhD, Principal investigator, Second Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07924501
- Sponsor's protocol ID
- AI-ECHO-SS-2025-001
- Status last verified
- Nov 2026
- First submitted
- 25 Oct 2026
- Last updated
- 9 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AI-ECHO-Based Intelligent Hemodynamic Subtyping and Dynamic Evolution in Septic Shock: A Prospective Observational Cohort Study
- ClinicalTrials.gov ID
- NCT07924501
- Acronym / sponsor ID
- AI-ECHO-SS-2025-001
- Conditions
- Sepsis, Septic Shock, Septic Cardiomyopathy
- Keywords
- Point-of-Care Echocardiography, Septic Shock, Hemodynamics, Intensive Care Unit, Left Ventricular Ejection Fraction, Global Longitudinal Strain
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital of Guangzhou Medical UniversityUniversity, hospital or other
- Collaborators
- Hong Kong University of Science and Technology
- Study start
- 30 Nov 2026 (estimated)
- Primary completion
- 9 Nov 2028 (estimated)
- Study completion
- 30 Nov 2028 (estimated)
- First posted
- 9 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. The study will enroll 240 adult patients with septic shock admitted to the ICU. Standardized cardiac ultrasound examinations will be performed at multiple time points, and multi-dimensional clinical-echocardiographic data will be collected. An AI-based automatic echocardiographic analysis system will be developed, and unsupervised machine learning will be applied to identify distinct hemodynamic subtypes and their dynamic evolution trajectories. This study aims to provide innovative solutions for individualized and precise hemodynamic management of septic shock.
Detailed description
Background
Septic shock is the most severe stage of sepsis and is associated with mortality as high as 40%-50%. Its pathophysiological core involves profound hemodynamic disturbances resulting from complex interactions among abnormal vascular tone, relative or absolute intravascular volume deficiency, myocardial depression, and microcirculatory dysfunction.
Accumulating evidence has demonstrated substantial heterogeneity in hemodynamic profiles among patients with septic shock, including hyperdynamic states, left ventricular systolic or diastolic dysfunction, right ventricular dysfunction, and various combined phenotypes. The traditional binary classification of "warm shock" versus "cold shock" is too simplistic to capture this complexity. Such heterogeneity may partly explain why uniform treatment strategies, such as early goal-directed therapy, have yielded inconsistent results and may cause iatrogenic harm in certain subgroups.
Echocardiography has become an important tool for hemodynamic assessment in the intensive care unit (ICU). It enables noninvasive, real-time evaluation of cardiac structure and function, including left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), right ventricular function, diastolic function, cardiac output, and volume status. However, its clinical utility is limited by:
- High operator dependency and interobserver variability;
- Time-consuming post-processing and interpretation;
- Difficulty in performing frequent dynamic assessments in busy ICU settings; and
- Limited integrated analysis of multiple parameters over time.
Recent advances in artificial intelligence (AI), particularly deep learning, have shown considerable promise in medical image analysis. In echocardiography, AI has demonstrated promising performance in view classification, cardiac structure segmentation, and automated measurement of functional parameters. Meanwhile, unsupervised machine learning methods provide potential approaches for identifying disease subtypes from high-dimensional clinical data.
Building on the established "Guangzhou Sepsis Cohort" and prior research experience in AI-assisted critical care medicine, this study will integrate AI and echocardiography to systematically characterize hemodynamic phenotypes and their dynamic evolution in patients with septic shock.
Study Design
This is a prospective, single-center, observational cohort study. A total of 360 adults with septic shock admitted to the ICU of The Second Affiliated Hospital of Guangzhou Medical University are anticipated to be consecutively enrolled.
Echocardiographic examinations will be performed on Day 1, Day 3, and Day 7 after enrollment. Clinical data, laboratory measurements, treatment information, and clinical outcomes will be collected according to the study protocol.
At each echocardiographic time point, standardized point-of-care echocardiography will be performed using the same model of ultrasound system and a phased-array transducer. Cine loops of the apical four-chamber, two-chamber, and three-chamber views will be acquired for at least three cardiac cycles. Additional Doppler, M-mode, right ventricular-focused, left ventricular outflow tract, and inferior vena cava recordings will be acquired as required for the prespecified echocardiographic measurements and as detailed in the imaging manual. All images will be stored in de-identified DICOM format using a unique study identification code.
AI-derived measurements will be used for research purposes only and will not guide clinical management. Clinical treatment will be determined by the treating clinical team and will not be assigned by the study.
Clinical data collected at or near the echocardiographic examinations will include vital signs, laboratory measurements, fluid balance, vasopressor dosage, and other treatment information. Blood samples will be collected on Day 1, Day 3, and Day 7 for targeted proteomic and metabolomic analyses, as specified in the study protocol.
Study Objectives
Primary Objective:
To identify and characterize distinct hemodynamic subtypes of septic shock using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters.
Secondary Objectives:
- Longitudinal changes and dynamic evolution of hemodynamic status within 7 days after enrollment;
- Associations of hemodynamic phenotypes with clinical severity and clinical outcomes;
- Agreement between AI-derived and blinded expert echocardiographic measurements;
- Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes; and
- Exploratory development and internal validation of an early-warning model for 28-day all-cause mortality.
Study Population
Adults (≥18 years) with septic shock, diagnosed according to the Sepsis-3 criteria, who meet the eligibility criteria listed in the Eligibility section will be consecutively enrolled from the ICU of The Second Affiliated Hospital of Guangzhou Medical University. Eligible participants must have an expected ICU stay of at least 72 hours, and written informed consent must be obtained from the patient or a legally authorized representative.
Outcome Measures
Primary Outcome:
Hemodynamic subtypes identified using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters collected within 7 days after enrollment.
Secondary Outcomes:
- Agreement between AI-derived echocardiographic measurements and blinded expert reference measurements, evaluated using intraclass correlation coefficients and Bland-Altman analyses;
- Associations between hemodynamic subtypes and 28-day mortality;
- Associations between hemodynamic subtypes and organ failure severity, as assessed by the Sequential Organ Failure Assessment (SOFA) score;
- Duration of vasopressor use; and
- ICU and hospital lengths of stay.
Statistical Analysis
Sample Size Considerations: The planned enrollment of 240 participants is based on the anticipated number of eligible septic shock admissions during the recruitment period, expected consent and follow-up completion, and study feasibility. The target sample size is intended to provide an adequate dataset for exploratory hemodynamic phenotyping and longitudinal echocardiographic analyses. As the primary objective is exploratory hemodynamic phenotyping using unsupervised analysis, no formal hypothesis-based power calculation was performed. Analyses of clinical outcomes, multi-omics profiles, and early-warning models will be considered exploratory, and model complexity will be limited according to the effective sample size and number of observed events.
Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, as appropriate. Categorical variables will be summarized as frequencies and percentages.
An unsupervised Gaussian mixture model will be applied to identify hemodynamic subtypes based on prespecified echocardiographic parameters. Clinical characteristics, treatment information, and outcomes will be compared among the identified subtypes.
Agreement between AI-derived measurements and blinded expert reference measurements will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. Targeted proteomic and metabolomic analyses will evaluate associations between protein or metabolite abundances and hemodynamic phenotype membership using methods appropriate for high-dimensional data. Where applicable, the false discovery rate will be used to account for multiple comparisons. These analyses will be considered exploratory.
An exploratory early-warning model for 28-day all-cause mortality will be developed using prespecified candidate predictors. Model discrimination will be assessed using the area under the receiver operating characteristic curve, and calibration will be evaluated using calibration plots and calibration statistics. Internal validation will be performed using bootstrap resampling or cross-validation. The number of candidate predictors and model complexity will be limited according to the number of observed events to reduce the risk of overfitting.
Multivariable logistic regression or Cox proportional hazards models will be constructed, as appropriate, to explore factors associated with adverse clinical outcomes. Repeated measurements and missing data will be addressed according to the prespecified statistical analysis plan.
Statistical analyses will be performed using SPSS, R, and Python. A two-sided P value <0.05 will be considered statistically significant, with exploratory analyses interpreted accordingly.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Septic Shock Patients | – | Other: Point-of-care echocardiographyAdults with septic shock admitted to the intensive care unit who meet the eligibility criteria listed in the Eligibility section. Participants will undergo standardized point-of-care echocardiography on Day 1, Day 3, and Day 7 after enrollment, together with clinical data and blood sample collection as specified in the study protocol. Clinical management will be determined by the treating clinical team and will not be assigned by the study. AI-derived echocardiographic measurements will be used for research purposes only and will not guide clinical management. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a prospective observational cohort study enrolling adult patients with septic shock admitted to the ICU. The study aims to construct a multi-dimensional clinical-echocardiographic database, develop an AI-based automatic echocardiographic analysis system, identify hemodynamic subtypes using unsupervised machine learning, and reveal the dynamic evolution patterns of hemodynamics in septic shock.
Key inclusion criteria (4 listed)
- Age ≥18 years.
- Confirmed diagnosis of septic shock according to the Sepsis-3 criteria.
- Expected ICU stay of at least 72 hours.
- Written informed consent obtained from the patient or legally authorized representative.
Key exclusion criteria (6 listed)
- Severe chronic heart disease, such as severe valvular heart disease or chronic heart failure with left ventricular ejection fraction (LVEF) <30%.
- Acute coronary syndrome.
- Status post cardiac surgery.
- Pregnancy.
- Inability to obtain high-quality echocardiographic images at screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Point-of-care echocardiographyStandardized point-of-care echocardiography will be performed on Day 1, Day 3, and Day 7 after enrollment. Images will be acquired according to the imaging manual and stored in de-identified DICOM format using a unique study identification code. Echocardiographic parameters will be used for hemodynamic phenotyping and assessment of changes over time. | Other | Septic Shock Patients |
Primary outcome
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock
Time frame: Within 7 days after enrollment
Identification and characterization of distinct hemodynamic phenotypes in adults with septic shock using unsupervised analysis of prespecified multidimensional echocardiographic parameters. The parameters may include measures of left ventricular systolic and diastolic function, right ventricular function, cardiac output or flow, and inferior vena cava dynamics, depending on data availability and image quality. The number and characteristics of the identified phenotypes will be determined using prespecified model selection and evaluation procedures.
5 secondary outcomes
Longitudinal Changes and Dynamic Evolution of Hemodynamic Status
Time frame: Day 1, Day 3, and Day 7 after enrollment.
Associations Between Hemodynamic Phenotypes and Clinical Severity and Outcomes
Time frame: Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
Agreement Between AI-Derived and Blinded Expert Echocardiographic Measurements
Time frame: Day 1, Day 3, and Day 7 after enrollment.
Associations Between Molecular Profiles and Hemodynamic Phenotypes
Time frame: Day 1, Day 3, and Day 7 after enrollment.
Exploratory Early-Warning Model for 28-Day All-Cause Mortality
Time frame: Predictors within 7 days; mortality through 28 days after enrollment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Sepsis
Not yet recruitingObservational study
Restricted or Liberal Fluid for Haemodynamic Resuscitation in Sepsis
Septic Shock, Fluid Resuscitation
Active, not recruitingPhase 3
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Shock, Septic
RecruitingPhase 1
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Chronic Granulomatous Disease, Infection
RecruitingPhase 1
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Malaria
Recruiting
A Platform Trial for Gram Negative Bloodstream Infections
Gram-negative Bacteremia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Weiyan Chen, MD, PhD principal investigator
Second Affiliated Hospital of Guangzhou Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis and Septic Shock, run by Second Affiliated Hospital of Guangzhou Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Weiyan Chen, MD, PhD (+86 13751845652, sam11124@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock (time frame: Within 7 days after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2026.